- Home
- NGNE vs PBFS Comparison
NGNE vs PBFS Comparison
Compare NGNE & PBFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- PBFS
- Stock Information
- Founded
- NGNE 2003
- PBFS 1889
- Country
- NGNE United States
- PBFS United States
- Employees
- NGNE N/A
- PBFS N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- PBFS Banks
- Sector
- NGNE Health Care
- PBFS Finance
- Exchange
- NGNE Nasdaq
- PBFS Nasdaq
- Market Cap
- NGNE 325.3M
- PBFS 311.6M
- IPO Year
- NGNE N/A
- PBFS N/A
- Fundamental
- Price
- NGNE $18.48
- PBFS $13.11
- Analyst Decision
- NGNE Strong Buy
- PBFS
- Analyst Count
- NGNE 7
- PBFS 0
- Target Price
- NGNE $41.86
- PBFS N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- PBFS 23.1K
- Earning Date
- NGNE 08-11-2025
- PBFS 08-08-2025
- Dividend Yield
- NGNE N/A
- PBFS N/A
- EPS Growth
- NGNE N/A
- PBFS 50.26
- EPS
- NGNE N/A
- PBFS 0.91
- Revenue
- NGNE N/A
- PBFS $91,369,000.00
- Revenue This Year
- NGNE N/A
- PBFS N/A
- Revenue Next Year
- NGNE N/A
- PBFS N/A
- P/E Ratio
- NGNE N/A
- PBFS $14.40
- Revenue Growth
- NGNE N/A
- PBFS 23.15
- 52 Week Low
- NGNE $6.88
- PBFS $10.60
- 52 Week High
- NGNE $74.49
- PBFS $13.41
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- PBFS 60.18
- Support Level
- NGNE $19.59
- PBFS $12.78
- Resistance Level
- NGNE $20.46
- PBFS $13.41
- Average True Range (ATR)
- NGNE 1.23
- PBFS 0.28
- MACD
- NGNE -0.20
- PBFS 0.02
- Stochastic Oscillator
- NGNE 13.37
- PBFS 67.39
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.